NCT06272799View on ClinicalTrials.gov

Tolerability and Efficacy of Adjuvant T-DM1 in Patients with HER2 Positive Breast Cancer After Incomplete Pathological Response to Neoadjuvant Chemotherapy Including Anti-HER2 Agents.

RecruitingOBSERVATIONAL

Enrollment

160

Participants

Timeline

Start Date

September 20, 2022

Primary Completion Date

September 20, 2024

Study Completion Date

September 20, 2024

Conditions

Breast Cancer

Interventions

DRUG

T-DM1 adjuvant

Evaluate the tolerability of treatment with adjuvant T-DM1 after failure to respond complete pathology to neoadjuvant treatment in terms of adverse events

Trial Locations (1)

00144

RECRUITING

"Regina Elena" National Cancer Institute, Rome

All Listed Sponsors

lead

Regina Elena Cancer Institute

OTHER